Treating heart failure with cardiac contractility modulation electrical signals

Current Heart Failure Reports

Volumn 3, Issue 1, 2006, Pages 21-24

  Sabbah, Hani N ^a   Gupta, Ramesh C ^b   Rastogi, Sharad ^b   Mishra, Sudhish ^b   Mika, Yuval ^b   Burkhoff, Daniel ^b  

^a HENRY FORD HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN SERCA2A; SODIUM CALCIUM EXCHANGE PROTEIN; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EFFECTIVENESS; DEVICE; DISEASE COURSE; DISEASE SEVERITY; DOG; ELECTRICITY; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; ELECTROSTIMULATION THERAPY; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; INSTRUMENTATION; METHODOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALS; DOGS; ELECTRIC STIMULATION THERAPY; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; PACEMAKER, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33749159995     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-006-0027-5     Document Type: Review

References (34)

1. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293-302.
2. Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HP). MERIT-HF Study Group. JAMA 2000, 283:1295-1302.
3. Pitt B, Zannad F, Remmee WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
4. Abraham WT, Fisher WG, Smith AL, et al.: Cardiac synchronization in chronic heart failure. N Engl J Med 2002, 346:1845-1853.
5. Saavedra WF, Paolocci N, Mishima T, et al.: Reverse remodeling and enhanced adrenergic reserve from passive external support in experimental dilated heart failure. J Am Coll Cardiol 2002, 39:2069-2076.
6. Pappone C, Rosanio S, Burkhoff D, et al.: Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002, 90:1307-1313.
7. Morita H, Suzuki G, Haddad W, et al.: Cardiac contractility modulation with non-excitatory electric signals improves left ventricular function in dogs with chronic heart failure. J Card Failure 2003, 9:69-75. This article describes the hemodynamic and ventriculographic results of acute delivery of CCM electrical signals to the LV myocardium of dogs with experimentally-induced HF. In this study, leads attached to the epicardial surface of the heart were used to deliver the CCM signals.
8. Morita H, Suzuki G, Haddad, et al.: Long-term effects of non-excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs. Eur J Heart Fail 2004, 6:145-150. This article describes the hemodynamic and ventriculographic results of the first chronic delivery of CCM electrical signals to the LV myocardium of dogs with experimentally-induced HF. In this study, a lead positioned in the anterior cardiac vein, via the coronary sinus, was used to deliver the CCM signals.
9. Auricchio A, Stellbrink C, Sack S, et al.: Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002, 39:2026-2033.
10. St John Sutton MG, Plappert T, Abraham WT, et al.: Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107:1985-1990.
11. Kass DA: Ventricular resynchronization: pathophysiology and identification of responders. Rev Cardiovasc Med 2003, 4(Suppl 2):S3-S13.
12. Yu CM, Yang H, Lau CP, et al.: Regional left ventricle mechanical asynchrony in patients with heart disease and normal QRS duration: implication for biventricular pacing therapy. Pacing Clin Electrophysiol 2003, 26:562-570.
13. Morris-Thurgood JA, Turner MS, Nightingale AK, et al.: Pacing in heart failure: improved ventricular interaction in diastole rather than systolic re-synchronization. Europace 2000, 2:271-275.
14. Sandhu R, Bahler RC: Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. Am J Cardiol 2004, 93:244-246.
15. Shenkman HJ, Pampati V, Khandelwal AK, et al.: Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002, 122:528-534.
16. Burkhoff D, Shemer I, Felzen B, et al.: Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart Fail Rev 2001, 6:27-34.
17. Mohri S, Shimizu J, Mika Y, et al.: Electric currents applied during the refractory period increased peak intracellular calcium and contractility in ferret hearts. Am J Physiol 2003, 284:H1119-H1123.
18. Mishra S, Gupta RC, Rastogi S, Haddad W: Short-term therapy with non-excitatory cardiac contractility modulation electric signals increases phosphorylation of phospholamban in left ventricular myocardium of dogs with chronic heart failure [abstract]. Circulation 2004, 110:111-604.
19. Rastogi S, Mishra S, Habib O, et al.: Therapy with non-excitatory cardiac contractility modulation electric signals reverses the maladaptive fetal gene program in LV myocardium of dogs with heart failure [abstract]. Circulation 2003, 108:IV-444.
20. Hasenfuss G, Reinecke H, Studer R, et al.: Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994, 75:434-442.
21. Frank KF, Bolck B, Brixius K, et al.: Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol 2002, 97(Suppl 1):I72-I78.
22. Mishra S, Gupta RC, Tiwari N, et al.: Molecular mechanisms of reduced sarcoplasmic reticulum Ca(2+) uptake in human failing left ventricular myocardium. J Heart Lung Transplant 2002, 21:366-373.
23. O'Rourke B, Kass DA, Tomaselli GF, et al.: Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 1999, 84:562-570.
24. Haghighi K, Gregory KN, Kranias EG: Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 2004, 322:1214-1222.
25. Frank K, Kranias EG: Phospholamban and cardiac contractility. Ann Med 2000, 32:572-578.
26. Schmidt U, Hajjar RJ, Kim CS, et al.: Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 1999, 277:H474-H480.
27. Schwinger RH, Munch G, Bolck B, et al.: Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 1999, 31:479-491.
28. Studer R, Reinecke H, Bilger J, et al.: Gene expression of the cardiac Na+ -Ca2+ exchanger in end-stage human heart failure. Circ Res 1994, 75:443-453.
29. Gupta RC, Mishra M, Rastogi S, et al.: Non-excitatory cardiac contractility modulation electric signals normalize phosphorylation and expression of the sodium-calcium exchanger in left ventricular myocardium of dogs with heart failure [abstract]. J Am Coll Cardiol 2005, 45:151A.
30. Gupta RC, Mishra S, Imai M, et al.: Cardiac contractility modulation with non-excitatory electric signals normalizes expression of the transcriptional factor GATA-4 in dogs with chronic heart failure [abstract]. Heart Rhythm 2005, 2:8138.
31. Sabbah HN, Imai M, Haddad W, et al.: Non-excitatory cardiac contractility modulation electric signals improve left ventricular function in dogs with heart failure without increasing myocardial oxygen consumption [abstract]. Heart Rhythm 2004, 1:S181.
32. Sabbah HN, Imai M, Rastogi S, Sharma N, et al.: Chronic therapy with non-excitatory cardiac modulation signals improves left ventricular function, reduces myocardial oxygen consumption and increases myocardial efficiency [abstract]. Heart Rhythm 2005, 2:S44.
33. Stix G, Borggrefe M, Wolpert C, et al.: Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J 2004, 25:650-655. This is the first report of the use of CCM electrical signals in patients with advanced HF.
34. Pappone C, Augello G, Rosanio S, et al.: First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study. J Cardiovasc Electrophysiol 2004, 15:418-427. This article documents the first study that CCM electrical signals were used to assess both safety and efficacy trends in patients with HF.